These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28324429)

  • 1. Identification of potential inhibitor targeting enoyl-acyl carrier protein reductase (InhA) in Mycobacterium tuberculosis: a computational approach.
    Shanthi V; Ramanathan K
    3 Biotech; 2014 Jun; 4(3):253-261. PubMed ID: 28324429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of mechanism of interaction of truncated isoniazid-nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach.
    Jena L; Deshmukh S; Waghmare P; Kumar S; Harinath BC
    Int J Mycobacteriol; 2015 Dec; 4(4):276-83. PubMed ID: 26964808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel antitubercular compounds through hybrid virtual screening approach.
    Muddassar M; Jang JW; Hong SK; Cho YS; Kim EE; Keum KC; Oh T; Cho SN; Pae AN
    Bioorg Med Chem; 2010 Sep; 18(18):6914-21. PubMed ID: 20727773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
    Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
    J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
    Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
    J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
    Saharan VD; Mahajan SS
    Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach.
    Stigliani JL; Arnaud P; Delaine T; Bernardes-Génisson V; Meunier B; Bernadou J
    J Mol Graph Model; 2008 Nov; 27(4):536-45. PubMed ID: 18955002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational approach to understanding the mechanism of action of isoniazid, an anti-TB drug.
    Jena L; Waghmare P; Kashikar S; Kumar S; Harinath BC
    Int J Mycobacteriol; 2014 Dec; 3(4):276-82. PubMed ID: 26786627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.
    Rawat R; Whitty A; Tonge PJ
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13881-6. PubMed ID: 14623976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
    Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of some novel pyrazolo[1,5-a]pyrimidine derivatives as InhA inhibitors through pharmacophore-based virtual screening and molecular docking.
    Modi P; Patel S; Chhabria MT
    J Biomol Struct Dyn; 2019 Apr; 37(7):1736-1749. PubMed ID: 29663870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
    Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
    J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding.
    Duca G; Pogrebnoi S; Boldescu V; Aksakal F; Uncu A; Valica V; Uncu L; Negres S; Nicolescu F; Macaev F
    Curr Top Med Chem; 2019; 19(8):609-619. PubMed ID: 30834838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity.
    Guardia A; Gulten G; Fernandez R; Gómez J; Wang F; Convery M; Blanco D; Martínez M; Pérez-Herrán E; Alonso M; Ortega F; Rullás J; Calvo D; Mata L; Young R; Sacchettini JC; Mendoza-Losana A; Remuiñán M; Ballell Pages L; Castro-Pichel J
    ChemMedChem; 2016 Apr; 11(7):687-701. PubMed ID: 26934341
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Jagadeb M; Rath SN; Sonawane A
    J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel potential antibiotics for tuberculosis by in silico structure-based drug screening.
    Izumizono Y; Arevalo S; Koseki Y; Kuroki M; Aoki S
    Eur J Med Chem; 2011 May; 46(5):1849-56. PubMed ID: 21397998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docking studies on novel alkaloid tryptanthrin and its analogues against enoyl-acyl carrier protein reductase (InhA) of Mycobacterium tuberculosis.
    Tripathi A; Wadia N; Bindal D; Jana T
    Indian J Biochem Biophys; 2012 Dec; 49(6):435-41. PubMed ID: 23350278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Novel Inhibitor of Enoyl-Acyl Carrier Protein Reductase (InhA) Enzyme in
    Singh K; Pandey N; Ahmad F; Upadhyay TK; Islam MH; Alshammari N; Saeed M; Al-Keridis LA; Sharma R
    Antibiotics (Basel); 2022 Aug; 11(8):. PubMed ID: 36009907
    [No Abstract]   [Full Text] [Related]  

  • 19. A QSAR and molecular modelling study towards new lead finding: polypharmacological approach to Mycobacterium tuberculosis.
    Janardhan S; John L; Prasanthi M; Poroikov V; Narahari Sastry G
    SAR QSAR Environ Res; 2017 Oct; 28(10):815-832. PubMed ID: 29183232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facing Antitubercular Resistance: Identification of Potential Direct Inhibitors Targeting InhA Enzyme and Generation of 3D-pharmacophore Model by in silico Approach.
    El Haddoumi G; Mansouri M; Bendani H; Bouricha EM; Kandoussi I; Belyamani L; Ibrahimi A
    Adv Appl Bioinform Chem; 2023; 16():49-59. PubMed ID: 37143606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.